Webinar: The future of Diabetic Neuropathy Management - May, 28th

Examining the Impact of Connected Devices on GLP-1 Therapy

Empowering Digital Health Programs to Make Swift Clinical Decisions

In a March 2024 survey, Withings Health Solutions asked their database of device users about their experience with GLP-1 treatments and the biomarkers they’ve been monitoring throughout their health journey, garnering responses from 2352 participants.

Part 3: Supporting Safe and Sustainable Weight Loss With GLP-1s – Managing weight after medication

Weight gain is likely when patients stop taking a GLP-1 therapy. A 2022 study found patients who took the GLP-1 semaglutide had regained two thirds of their prior weight and had similar cardiometabolic changes a year after stopping the medication. Prescribers at doctor’s offices and virtual weight loss programs should track patients throughout their journey and when they stop taking GLP-1s. This monitoring of daily progress provides long-term oversight of weight loss goals and maintenance.